Press Releases

January 23, 2012

NovaBay Prepares to Launch Global Phase 2b Ophthalmic Study of NVC-422

January 9, 2012

NovaBay Pharmaceuticals Announces Strategic Marketing Agreement for NeutroPhase in China

November 30, 2011

NovaBay Establishes Primary Proof of Concept for NVC-422 Phase 2 UCBE Clinical Program

November 14, 2011

NovaBay Pharmaceuticals' Aganocide Compound, NVC-422, Featured in Drugs of the Future

November 7, 2011

NovaBay Pharmaceuticals Reports Third Quarter Financial Results

October 14, 2011

NovaBay Pharmaceuticals Spotlights NeutroPhase at the Symposium on Advanced Wound Care (SAWC)

October 4, 2011

NovaBay Pharmaceuticals Names David W. Stroman, Ph.D. As Head of Ophthalmic Drug Development

September 28, 2011

NovaBay Pharmaceuticals Names Russell A. Hoon As Vice President of its Advanced Wound Care Business Unit

September 21, 2011

NovaBay Pharmaceuticals to Present at the LD MICRO Invitational Conference

September 12, 2011

NovaBay Pharmaceuticals Reports Positive Results in Sinus Infection Study

August 25, 2011

NovaBay Pharmaceuticals Highlighted in Cataract & Refractive Surgery Today

August 24, 2011

NovaBay Pharmaceuticals to Present at The 2011 Southern California Investor Conference

August 10, 2011

NovaBay Pharmaceuticals Reports Second Quarter Financial Results

July 11, 2011

NovaBay Pharmaceuticals Provides Business Update

July 5, 2011

NovaBay Pharmaceuticals Announces the Closing of its $5.2 Million Registered Direct Offering of Common Stock and Warrants

June 29, 2011

NovaBay Pharmaceuticals, Inc. Announces Pricing of a $5.2 Million Registered Direct Offering of Common Stock and Warrants

June, 16, 2011

NovaBay Regains Worldwide Rights to Its Aganocide Compounds from Alcon

May 23, 2011

NovaBay Pharmaceuticals to Present at the 7th Annual Spring Growth Stock Conference Hosted by Security Research Associates, Inc. on May 24

May 18, 2011

Archive of Conference call Re: Results from Phase 2 Clinical Study for the Treatment of Adenoviral Conjunctivitis
Click Here To Listen

May 18, 2011

NovaBay Pharmaceuticals Reports Results from Phase 2 Clinical Trial of NVC-422 for Adenoviral Conjunctivitis

May 16, 2011

NovaBay Pharmaceuticals, Inc. Reports First Quarter Financial Results

May 6, 2011

NovaBay Pharmaceuticals Spotlights Three New Aganocide Compounds with Confirmed Activity against Ophthalmic Pathogens

April 19, 2011

NovaBay Pharmaceuticals Spotlights Positive Results From NeutroPhase Study of 26 Patients With Chronic Non-Healing Wounds

April 14, 2011

NovaBay Pharmaceuticals Awarded 1st Place for Outstanding Scientific Presentation at The Simon Foundation for Continence Conference

April 12, 2011

NovaBay Pharmaceuticals Spotlights Positive Results for Its Novel Anti-Infective at 2011 Simon Foundation for Continence Conference

March 28, 2011

NovaBay Pharmaceuticals Releases CEO Webcast on Business and Clinical Developments from Its Four Business Units - Click Icon Below

March 28, 2011

NovaBay Pharmaceuticals Releases CEO Webcast on Business and Clinical Developments from Its Four Business Units

March 10, 2011

NovaBay Pharmaceuticals Provides Fourth Quarter and Full Year 2010 Financial Results and Business Unit Updates

March 9, 2011

NovaBay Pharmaceuticals to Present at the Roth Capital 23rd Annual Growth Stock Conference on March 16

March 2, 2011

NovaBay Pharmaceuticals Initiates Phase 2 Clinical Trial for the Treatment of Urinary Catheter Blockage and Encrustation

February 18, 2011

NovaBay Pharmaceuticals Ranked No. 7 in Biotech Industry in Fast Company's Annual List of World's Most Innovative Companies

February 8, 2011

NovaBay Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference

February 2, 2011

NovaBay Pharmaceuticals Provides Summary of 2010 Accomplishments and 2011 Outlook

January 7, 2011

NovaBay Pharmaceuticals to Present at 2011 Biotech Showcase Conference

January 6, 2011

NovaBay Pharmaceuticals Reports Activity of Aganocide NVC-422 Against Deadly "Superbug" producing NDM-1 (New Delhi Metallo-beta-lactamase-1)

December 16, 2010

NovaBay Pharmaceuticals CEO Contributes Article to The Scientist

December 6, 2010

NovaBay Pharmaceuticals and Galderma Expand Their Agreement to Include Impetigo

December 2, 2010

NovaBay Pharmaceuticals to Present at the 3rd Annual LD MICRO Conference

November 29, 2010

NovaBay Pharmaceuticals Holds Successful FDA Meeting on Clinical Development of Aganocide® Compound NVC-422 for Impetigo

November 12, 2010

NovaBay Pharmaceuticals, Inc. Reports Third Quarter Financial Results

November 8, 2010

NovaBay Pharmaceuticals Awarded Cash Grant Under the U.S. Government Qualifying Therapeutic Discovery Program

November 4, 2010

NovaBay Pharmaceuticals to Present at Two Upcoming Investor Conferences in November

October 25, 2010

NovaBay Pharmaceutical’s NVC-422 Demonstrates up to 95% Efficacy in 129 Patient Impetigo Phase 2 Clinical Trial, Including 100% Efficacy in MRSA Infected Patients

October 18, 2010

NovaBay Pharmaceuticals Reports on Status of Phase 2 Proof of Concept Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis

October 15, 2010

NovaBay Pharmaceuticals to Present Human Clinical Data on Lead Anti-infective Compound at the 48th Annual IDSA Meeting

October 11, 2010

NovaBay Pharmaceuticals Appoints Gail Maderis, BayBio President and CEO and Former Genzyme Senior Executive, to Its Board of Directors

September 16, 2010

NovaBay Pharmaceuticals Spotlights Positive Results for New Class of Anti-infectives at 50th Annual ICAAC Meeting

August 24, 2010

NovaBay Pharmaceuticals Announces Resignation of Board Member

August 12, 2010

NovaBay Pharmaceuticals, Inc. Reports Second Quarter Financial Results

"The Pink Sheet" - July 26, 2010

NovaBay's Non-Antibiotic Anti-Infective Shows Efficacy In Impetigo Trial

July 21, 2010

NovaBay Pharmaceuticals' Non-antibiotic Anti-infective Successful in Phase 2 Skin Infection Trial

July 15, 2010

NovaBay Pharmaceuticals Receives Notice of Allowance on Anti-infective NVC-612 and Related Compounds

May 25, 2010

NovaBay Pharmaceuticals Completes Enrollment in Phase 2 Impetigo Clinical Trial

May 12, 2010

NovaBay Pharmaceuticals, Inc. Reports First Quarter Financial Results

May 6, 2010

Positive Data on New Class of Anti-infectives Announced by NovaBay Pharmaceuticals at ARVO 2010

April 30, 2010

NovaBay Pharmaceuticals Announces New Data on First-in-Class Anti-infective Compounds at ARVO Annual Meeting

April 23, 2010

NovaBay Pharmaceuticals to Present at BIO 2010 International Convention

April 15, 2010

NovaBay Pharmaceuticals Reports Positive Data from Exploratory Phase 2 Trial

March 29, 2010

NovaBay Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2009 Financial Results

February 04, 2010

NovaBay Pharmaceuticals to Present at the 2010 BIO CEO & Investor Conference

January 11, 2010

NovaBay Pharmaceuticals Earns $3.75 Million in Milestone Payments from Galderma, S.A.

January 7, 2010

NovaBay Pharmaceuticals to Present at the Annual OneMedPlace Finance Forum

December 17, 2009

NovaBay Pharmaceuticals to Receive Increase in Funding and Support from Alcon

November 13, 2009

NovaBay Pharmaceuticals Reports Third Quarter 2009 Financial Results, Provides Pipeline Update

October 30, 2009

NovaBay’s Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis

October 28, 2009

NovaBay to Hold Conference Call to Review Aganocide Data Presented at the Infectious Diseases Society of America Meeting

October 22, 2009

NovaBay Pharmaceuticals to Present at 8th Annual Bio Investor Forum 2009 in San Francisco

October 19, 2009

NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer

September 24, 2009

NovaBay Pharmaceuticals to Present at Maxim Group Growth Conference Presentation to be Webcast on September 29, 2009

September 22, 2009

NovaBay Pharmaceuticals Is Recognized As A New California 100 Business Innovator By Golden Capital Network & Hamilton Lane

September 14, 2009

NovaBay Presents Data Confirming Its Aganocide Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance

September 10, 2009

NovaBay Launches Clinical Study for Non-Antibiotic Treatment of Impetigo, One of the Most Common Skin Infections

September 3, 2009

NovaBay Pharmaceuticals to Present at Rodman & Renshaw 11th Annual Healthcare Conference September 10, 2009 in New York City

August 26, 2009

NovaBay Pharmaceuticals Announces the Closing of its $2.45 Million Registered Direct Offering of Common Stock and Warrants

August 24, 2009

NovaBay Pharmaceuticals to Present New Pre-Clinical Data on Lead Anti-Infective Compound for use in Onychomycosis at the 2009 IDSA Annual Meeting

August 21, 2009

NovaBay Pharmaceuticals Announces Pricing of Registered Direct Offering of Common Stock and Warrants

August 21, 2009

NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting

August 14, 2009

NovaBay Pharmaceuticals Reports Second Quarter 2009 Financial Results

Aug 3, 2009

NovaBay Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development

July 27, 2009

NovaBay Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference

July 05, 2009

Alcon Commences Phase 2 Clinical Trial of NovaBay’s NVC-422 for Viral Conjunctivitis

May 18, 2009

NovaBay Pharmaceuticals Reports First Quarter 2009 Financial Results

Apr 22, 2009

NovaBay Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide Compounds

Apr 7, 2009

NovaBay Pharmaceuticals Appoints Professor John A. Soderquist, Ph.D. to its Scientific Advisory Board

Apr 1, 2009

NovaBay Pharmaceuticals Announces Fourth Quarter and Full Year 2008 Financial Results

Mar 25, 2009

NovaBay Pharmaceuticals and Galderma Enter into Global Agreement to Develop and Commercialize NovaBay’s Novel Aganocide Drugs for Major Dermatological Conditions

Mar 23, 2009

NovaBay Pharmaceuticals Scientific Advisor Receives American Chemical Society’s Highest Award

Mar 7, 2009

NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection

Mar 4, 2009

NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67 Annual Meeting

Feb 23, 2009

NovaBay Pharmaceuticals Receives Broadcast And Print Media Coverage

Feb 4, 2009

NovaBay Pharmaceuticals CEO Dr. Ron Najafi To Present at the 11th Annual BIO CEO & Investor Conference

Jan 20, 2009

NovaBay Pharmaceuticals Appoints Harry F. Hixson, Jr., PhD, Former Amgen President/Chief Operating Officer To Its Board of Directors

Jan 13, 2009

NovaBay's NVC-422 Cleared by FDA for Human Clinical Trials in Ophthalmology

Jan 9, 2009

NovaBay Pharmaceuticals Issued Key Composition of Matter Patent for Aganocide Compounds

Jan 8, 2009

NovaBay Pharmaceuticals announces Retirement of Senior Executive

December 31, 2008

NovaBay Pharmaceuticals Plans to Consolidate its Stock Listing
on the American Stock Exchange (AMEX)

November 18, 2008

Patient Enrollment Begins in Exploratory Phase II Trial of Novabay's Lead Aganocide Compound, NVC-422, in Catherer-Associated Urinary Tract Infections

November 14, 2008

Novabay Pharmaceuticals Reports Third Quarter 2008 Financial Results

November 07, 2008

Novabay Pharmaceuticals To Present at the 10th Annual Rodman & Renshaw Healthcare Conference

October 29, 2008

What the World Needs Now: Safe Non-Antibiotic Anti-Infectives

October 27, 2008

The Future of Anti-Microbials is Here

October 23, 2008

NovaBay Pharmaceuticals To Present At The 7 Annual BIO Investor Forum

October 7, 2008

NovaBay Pharmaceuticals To Present Data On Lead Anti-Infective Compound at First-Ever ICAAC/IDSA Joint Meeting

October 1, 2008

NovaBay Pharmaceuticals to Present at the Maxim Group Annual Growth Conference

August 14, 2008

NovaBay to Present at 4th Annual Summer Technology Conference

August 14, 2008

NovaBay Pharmaceuticals Reports Second Quarter 2008 Financial Results

August 7, 2008

NovaBay Pharmaceuticals Featured on KGO-TV San Francisco

July 31, 2008

NovaBay Pharmaceuticals CEO, Dr. Ron Najafi, Joins Distinguished Leaders Selected For This Year’s PharmaVOICE 100 Most Influential Leaders

July 29, 2008

NovaBay Begins Media Education Initiative to Promote New Approaches to Treating “Super Bugs”

July 17, 2008

NovaBay Announces Advancements In Dermatology Program

June 16, 2008

NovaBay Pharmaceuticals To Present At The BIO International Convention

May 19, 2008

NovaBay Announces Positive Results From Phase IIa Study of AgaNase For Nasal Decolonization of Staph including MRSA

May 14, 2008

NovaBay Pharmaceuticals Reports First Quarter 2008 Results

May 12, 2008

NovaBay's Lead Aganocide Compound, NVC-422, Well Tolerated in the Bladder in Phase I Trial

March 18, 2008

NovaBay Pharmaceuticals Publishes on the Design of New Class of Antimicrobial Compounds It Named Aganocides

March 11, 2008

NovaBay Pharmaceuticals Reports Fourth Quarter and Year End 2007 Results –Provides Corporate Highlights

March 7, 2008

NovaBay Pharmaceuticals Commences Phase I Human Clinical Trial for the Prevention of Catheter Associated Urinary Tract Infections

March 4, 2008

NovaBay Pharmaceuticals, Inc. Announces Year End 2007 Earnings Conference Call

February 26, 2008

NovaBay Pharmaceuticals Presentation at the 20th Annual Roth Capital
OC Growth Stock Conference Featured on MSN Money

February 12, 2008

NovaBay Pharmaceuticals Receives Allowance of Patent Covering NeutroPhase™ Product

February 7, 2008

NovaBay Pharmaceuticals To Present At Two Upcoming Healthcare Conferences

February 5, 2008

NovaBay Informs Investors of Inaccuracies on Yahoo! Finance

January 28, 2008

NovaBay Pharmaceuticals Rang Opening Bell At The American Stock Exchange

January 22, 2008

NovaBay Pharmaceutical’s Investigational New Drug Application (IND) for the Prevention of Catheter Associated Urinary Tract Infections Cleared by FDA

January 10, 2008

NovaBay Pharmaceuticals Appoints Thomas J. Paulson Chief Financial Officer

December 5, 2007

NovaBay Pharmaceuticals to Present at the New York Society of
Security Analysts Biotech/Specialty Pharma Conference

November 26, 2007

Novabay Pharmaceuticals Announces Positive Phase 1 Study Results With Lead Aganocide Compound

November 20, 2007

NovaBay Pharmaceuticals Retains The Investor Relations Group of New York

NovaBay Pharmaceuticals Featured In November/December Issue of PharmaVOICE

November 15, 2007

NovaBay Pharmaceuticals Announces Third Quarter 2007 Financial Results

October 31, 2007

NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock

Novabay